MultiCell Technologies, Inc. (MCET)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Aug 1, 2025, 3:37 PM EDT

MultiCell Technologies Company Description

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications.

Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers.

The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications.

MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004.

MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.

MultiCell Technologies, Inc.
CountryUnited States
Founded1962
IndustryBiotechnology
SectorHealthcare
Employees2
CEOW. Newmin

Contact Details

Address:
68 Cumberland Street
Woonsocket, Delaware 02895
United States
Phone401 762 0045

Stock Details

Ticker SymbolMCET
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearDecember - November
Reporting CurrencyUSD
ISIN NumberUS62544S2005
SIC Code2836

Key Executives

NamePosition
W. Gerald NewminChairman, Chief Executive Officer, President, Chief Financial Officer, Treasurer and Secretary
Barbara CorbettManager of Investor Relations